Skye Bioscience, Inc. SEC filings SKYE

Skye Bioscience, Inc. has 631 filings in SEC EDGAR's recent list, going back to Mar 25, 2011. Its latest annual report, Form ARS, was filed on Apr 16, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 11, 2026 (agreement ended, officer or director change, other events). The company's fiscal year ends on December 31.

Skye Bioscience, Inc. SEC filings
Form Description Filed Period
ARS Annual report to shareholders Apr 16, 2026 Dec 31, 2025
10-K Annual report Mar 10, 2026 Dec 31, 2025
ARS Annual report to shareholders Apr 25, 2025 Dec 31, 2024
10-K Annual report Mar 20, 2025 Dec 31, 2024
10-K Annual report Mar 22, 2024 Dec 31, 2023
10-K Annual report Mar 31, 2023 Dec 31, 2022
10-K Annual report Mar 28, 2022 Dec 31, 2021
10-K Annual report Mar 2, 2021 Dec 31, 2020
10-K Annual report Mar 23, 2020 Dec 31, 2019
10-K/A Amended annual report May 29, 2019 Dec 31, 2018
10-K Annual report Mar 14, 2019 Dec 31, 2018
10-K Annual report Mar 19, 2018 Dec 31, 2017
10-K Annual report Mar 10, 2017 Dec 31, 2016
10-K Annual report Mar 21, 2016 Dec 31, 2015
10-K Annual report Mar 27, 2015 Dec 31, 2014
10-K Annual report Jan 27, 2014 Oct 31, 2013

Showing 16 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
SKYE (Nasdaq)
Fiscal year ends
December 31
Incorporated in
NV
Headquarters
San Diego, CA
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1516551
Former names
Emerald Bioscience, Inc. (until Jan 7, 2021); Nemus Bioscience, Inc. (until Mar 14, 2019); LOAD GUARD LOGISTICS, INC. (until Oct 30, 2014); LOAD GUARD TRANSPORTATION, INC. (until Nov 7, 2012)

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.